Nimid granules for oral suspension sachet 2 g, 100 mg/2 g, 30 pcs.

When to use

Indications for use for tablets and granules:

• relief of pain in diseases of the musculoskeletal and musculoskeletal system (osteoarthrosis, osteochondrosis, tendinitis, bursitis, arthritis);
• pain relief for injuries and postoperative pain;
• symptomatic treatment of female diseases, diseases of the ENT organs, urinary tract;
• toothache;
• high temperature due to infectious diseases.

The gel is used externally for injuries and diseases of joints and connective tissues. Indications for use: rheumatism, gout, myalgia, lumbago, sciatica, neuralgia, soft tissue bruises. The remedy is indicated for acute inflammatory processes and is effective against stiffness of movement.

Contraindications and side effects

The medicine is not used for patients with hypersensitivity to the active substance and auxiliary components.

Other contraindications:

• allergic reactions to drugs from the NSAID group and acetylsalicylic acid;
• acute and subacute ulcers of the stomach and duodenum;
• cerebral hemorrhage;
• severe cardiovascular pathologies;
• severe forms of renal and liver failure;
• alcoholism and drug addiction;
• viral infections;
• suspicion of the need for surgical intervention;
• age up to 12 years.

Nimid for back pain in gel form is not used if the skin area has dermatitis or wounds. The gel is also contraindicated in persons with a history of bronchial asthma provoked by taking drugs containing ASA.

Side effects may occur while taking the medication:

• allergic reactions on the skin (rash, peeling, itching);
• swelling;
• anemia;
• dizziness;
• temporary decrease in visual acuity;
• increased blood pressure;
• bronchospasm;
• nausea, vomiting;
• gastrointestinal bleeding;
• gastrointestinal disorder;
• cholestasis;
• difficulty urinating;
• sense of anxiety.

Treatment varies depending on the severity of the reaction. In severe cases, the nonsteroidal drug is discontinued. Taking Nimid for cystitis requires the supervision of a urologist.

Nimid 100mg TB No. 10 (100)

Compound

active ingredient nimide: nimesulide (nimesulide); 1 tablet contains nimesulide 100 mg; nimide excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal anhydrous silicon dioxide.

DOSAGE FORM.

Nimid tablets.

BASIC PHYSICAL AND CHEMICAL PROPERTIES.

Nimid - round tablets of light yellow color, smooth on both sides.

PHARMACOTHERAPEUTIC GROUP.

Nimid tablets are nonsteroidal anti-inflammatory and antirheumatic drugs. ATX code M01A X17.

PHARMACOLOGICAL PROPERTIES.

Pharmacodynamics.

Nimid is a non-steroidal anti-inflammatory drug of the methanesulfonanilide group, which exhibits anti-inflammatory, analgesic and antipyretic effects. The therapeutic effect of the drug Nimid is due to the fact that it interacts with the arachidonic acid cascade and reduces the biosynthesis of prostaglandins by inhibiting cyclooxygenase. Pharmacokinetics.

In humans, nimide is well absorbed when taken orally, reaching maximum plasma concentrations after 2-3 hours. Up to 97.5% of nimesulide binds to plasma proteins. Nimid is actively metabolized in the liver with the participation of CYP2C9, an isoenzyme of cytochrome P450. The main metabolite is a parahydroxy derivative, which also has pharmacological activity. The half-life is from 3.2 to 6 hours. Nimid is excreted from the body in the urine - about 50% of the dose taken. About 29% of the dose taken is excreted in the feces in a metabolized form. Only 1-3% is excreted unchanged from the body. The pharmacokinetic profile does not change in elderly patients.

CLINICAL CHARACTERISTICS.

Indications

Nimid is prescribed for the treatment of acute pain and primary dysmenorrhea. Nimesulide should be used only as a second-line drug.

The decision to prescribe nimide tablets should be made based on an assessment of all the risks for a particular patient.

Contraindications

Known hypersensitivity to nimide or any other component of the drug.

History of hyperergic reactions (bronchospasm, rhinitis, urticaria) to the use of acetylsalicylic acid or other non-steroidal anti-inflammatory drugs. History of hepatotoxic reactions to nimesulide.

Concomitant use of other substances with potential hepatotoxicity.

Alcoholism and drug addiction.

History of gastrointestinal bleeding or perforation associated with previous use of non-steroidal anti-inflammatory drugs.

Gastric or duodenal ulcer in the acute phase, a history of ulcers, perforation or bleeding in the digestive tract.

A history of cerebrovascular bleeding or other hemorrhages, as well as diseases accompanied by bleeding.

Severe blood clotting disorders.

Severe heart failure.

Severe renal impairment.

Liver dysfunction.

Patients with fever and/or flu-like symptoms.

Children under 12 years of age are prohibited from using Nimid.

III trimester of pregnancy or breastfeeding period.

INTERACTIONS WITH OTHER MEDICINES AND OTHER TYPES OF INTERACTIONS.

PHARMACODYNAMIC INTERACTIONS.

Corticosteroids: Increases the risk of gastrointestinal ulcers or bleeding.

Antiplatelet agents and selective serotonin reuptake inhibitors (SSSRIs): increases the risk of bleeding in the digestive tract.

Anticoagulants: NSAIDs may potentiate the effect of anticoagulants such as warfarin or acetylsalicylic acid, which is why this combination is contraindicated in patients with severe coagulation disorders. If such combination therapy cannot be avoided, close monitoring of blood coagulation parameters is necessary.

Diuretics, angiotensin-converting enzyme inhibitors and angiotensin II antagonists.

Nimid tablets may reduce the effect of diuretics and other antihypertensive drugs. In some patients with impaired renal function (for example, dehydrated patients or elderly patients), concomitant use of ACE inhibitors, angiotensin II antagonists or substances that inhibit the cyclooxygenase system may cause further deterioration of renal function and acute renal failure, which is usually reversible. These interactions should be taken into account when a patient takes Nimid together with ACE inhibitors or angiotensin II antagonists. You should be very careful when using this combination, especially in elderly patients. Patients should receive adequate fluid intake and renal function should be closely monitored after starting this combination. Nimid temporarily weakens the effect of furosemide regarding sodium excretion and, to a lesser extent, potassium excretion, and also reduces the diuretic effect. The combined use of furosemide and Nimid in patients with impaired renal or cardiac function requires caution.

In healthy volunteers, nimide rapidly reduces the effect of furosemide on sodium excretion and, to a lesser extent, on potassium excretion, and also reduces the diuretic effect. The simultaneous use of nimesulide and furosemide leads to a decrease (by approximately 20%) in the area under the concentration-time curve (AUC) and a decrease in the cumulative excretion of furosemide without changes in the renal clearance of furosemide. Pharmacokinetic interactions with other drugs.

NSAIDs have been reported to decrease the clearance of lithium, resulting in increased plasma lithium levels and lithium toxicity. When prescribing Nimid to patients receiving lithium therapy, plasma lithium levels should be monitored frequently.

There is no clinically significant interaction with glibenclamide, theophylline, warfarin, digoxin, cimetidine and antacids (a combination of aluminum and magnesium hydroxide) in vivo. Nimid inhibits the activity of the CYP2C9 enzyme. When used simultaneously with Nimid, drugs that are substrates of this enzyme, their concentration in plasma may increase. Caution must be exercised if nimesulide is prescribed less than 24 hours before or less than 24 hours after taking methotrexate, since it is possible to increase the level of the latter in the blood serum and increase its toxicity.

Due to their effect on cellular prostaglandins, synthetase inhibitors, to which nimesulide belongs, can increase the nephrotoxicity of cyclosporines.

Effect of other drugs on nimide.

In vitro studies have shown that nimide is displaced from binding sites by tolbutamide, salicylic acid and valproic acid. Although these interactions were detected in blood plasma, these effects were not observed during clinical use of the drug.

FEATURES OF APPLICATION.

Undesirable side effects of Nimid tablets can be minimized by using the minimum effective dose for the shortest period of time necessary to control symptoms of the disease.

If treatment with Nimid tablets is not effective (reduction of disease symptoms), therapy should be discontinued.

During treatment with Nimid tablets, it is recommended to avoid the simultaneous use of hepatotoxic drugs, and also to refrain from drinking alcohol. The use of nonsteroidal anti-inflammatory drugs may mask the increase in body temperature associated with an underlying bacterial infection. If fever or flu-like symptoms occur in patients taking nimide, the drug should be discontinued.

There have been reports of serious liver reactions during treatment with Nimid Tablets, including death. Patients who experience symptoms similar to those of liver damage, such as anorexia, nausea, vomiting, abdominal pain, fatigue, dark urine, and patients whose liver function laboratory tests deviate from normal values, should stop taking the drug . Repeated administration of nimide to such patients is contraindicated. During treatment with Nimid, the patient should refrain from using other analgesics. Concomitant use of other NSAIDs, including selective cyclooxygenase-2 inhibitors, should be avoided.

Patients receiving Nimid tablets who develop flu-like symptoms should discontinue use.

Elderly patients have an increased incidence of adverse reactions to NSAIDs, especially with regard to possible bleeding and perforation in the digestive tract, which can be fatal.

An ulcer, bleeding or perforation in the digestive tract can threaten the patient’s life, especially if there is evidence in the patient’s history that similar phenomena have occurred while using any other NSAIDs (without a statute of limitations). The risk of such events increases with an increase in the dose of NSAIDs in patients with a history of ulcers in the digestive tract, especially complicated by bleeding or perforation, as well as in elderly patients. In such patients, treatment should begin with the lowest effective dose. For these patients, as well as for those who are concurrently taking low doses of acetylsalicylic acid or other drugs that increase the risk of gastrointestinal complications, combination therapy with protective substances, such as misoprostol or proton pump inhibitors, should be considered.

Patients with gastrointestinal toxicity, especially elderly patients, should report any unusual gastrointestinal symptoms, especially bleeding. This is especially important in the initial stages of treatment. Patients taking concomitant medications that increase the risk of ulceration or bleeding, such as corticosteroids, anticoagulants, selective serotonin reuptake inhibitors, antiplatelet agents (acetylsalicylic acid), should be advised to exercise caution when using nimesulide.

If a patient receiving Nimid tablets experiences bleeding or gastrointestinal ulcers, treatment with the drug should be discontinued.

NSAIDs should be prescribed with caution to patients with Crohn's disease or a history of ulcerative colitis, since nimide tablets can lead to their exacerbation. The simultaneous use of nimide tablets with other drugs, such as oral contraceptives, anticoagulants, antiplatelet agents, can cause exacerbation of Crohn's disease and other diseases of the digestive tract.

Patients with a history of arterial hypertension and/or heart failure, as well as patients with fluid retention in the body and edema due to the use of NSAIDs, require appropriate monitoring of their condition and consultation with a doctor.

Clinical studies and epidemiological data suggest that some NSAIDs, especially at high doses and with long-term use, may occasionally lead to arterial thrombotic episodes such as myocardial infarction and stroke. To exclude the risk of these phenomena occurring when using nimesulide, such data are insufficient.

In patients with uncontrolled arterial hypertension, acute heart failure, established coronary artery disease, peripheral arterial disease and/or cerebrovascular disease, nimide should be prescribed after a thorough assessment of the condition. The same should be done before prescribing the drug to patients with risk factors for developing cardiovascular diseases, for example, arterial hypertension, hyperlipidemia, diabetes mellitus, and smoking.

In patients with impaired renal function or heart failure, the drug should be prescribed with caution due to the possibility of deterioration of renal function. If the patient's condition worsens, treatment should be discontinued.

Elderly patients must be carefully monitored due to the possibility of bleeding and perforation of the digestive tract, impaired renal, liver or cardiac function. Since nimide tablets may affect platelet function, it should be administered with caution to patients with bleeding diathesis. However, nimesulide does not replace acetylsalicylic acid in the prevention of cardiovascular diseases.

There have been reports of rare cases of severe skin reactions with the use of Nimid tablets, some of which can be fatal, for example, exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis. In most cases, if these reactions occur during the first month of a previously prescribed course of treatment, the risk of their occurrence in patients increases significantly. Nimid should be discontinued at the first signs of skin rash, damage to the mucous membranes and other allergic manifestations.

USE DURING PREGNANCY OR BREAST-FEEDING

Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or fetal development. Data obtained from epidemiological studies allow us to conclude that in early pregnancy, the use of drugs that suppress prostaglandin synthesis increases the risk of involuntary abortion, heart defects and gastroschisis in the fetus. The absolute risk of developing a cardiovascular abnormality increased from less than 1% to approximately 1.5%. The risk is believed to increase with increasing dose and duration of use.

You should not take Nimid tablets during the first and second trimesters of pregnancy unless absolutely necessary. When using the drug in women who are trying to become pregnant, or in the first and second trimesters of pregnancy, the lowest possible dose and the shortest possible duration of treatment should be prescribed.

In the third trimester of pregnancy, all prostaglandin synthesis inhibitors can lead to the development in the fetus:

• pneumocardial toxic damage (with premature closure of the arterial ducts and hypertension in the pulmonary artery system);
• renal dysfunction, which can progress to renal failure with the development of oligohydramnios.

At the end of pregnancy, the mother and fetus may:

• increased bleeding time, antiaggregation effect, which can occur even when using very low doses of the drug;
• suppression of contractile activity of the uterus, which can lead to a delay or prolongation of the period of labor.

Therefore, nimide tablets are contraindicated in the third trimester of pregnancy.

As NSAIDs that suppress prostaglandin synthesis, nimesulide can cause premature closure of the ductus botellus, pulmonary hypertension, oliguria, and oligohydramnios. The risk of bleeding, weakness of labor and peripheral edema increases. There are isolated reports of renal failure in newborns whose mothers used nimesulide at the end of pregnancy. Animal studies have shown atypical reproductive toxicity of the drug, but there is no reliable data on the use of nimesulide in pregnant women. The potential risk for humans has not been determined; therefore, it is not recommended to prescribe nimesulide in the 1st and 2nd trimester of pregnancy. Since it is unknown whether nimesulide passes into breast milk, its use is contraindicated during breastfeeding.

Nimid tablets may impair fertility in women and are therefore not recommended for use by women who are trying to become pregnant. Women who are unable to become pregnant or women undergoing evaluation for infertility should consider stopping the use of nimesulide. If pregnancy is established during the use of nimesulide, the doctor should be informed about this.

THE ABILITY TO INFLUENCE THE SPEED OF REACTION WHEN DRIVING VEHICLES OR OTHER MECHANISMS.

No studies have been conducted on the effect of nimide on the ability to drive vehicles or use other mechanical equipment, but if patients experience headache, dizziness, or drowsiness when using nimide tablets, they should stop driving or using other machines.

Directions for use and doses

To minimize possible unwanted side effects of Nimid tablets, the minimum effective dose should be used for the shortest possible time. It is recommended to take it after meals and take it with plenty of liquid.

The maximum duration of treatment with Nimid tablets is 15 days.

Adults. 1 tablet (100 mg) 2 times a day.

Elderly patients. No dose adjustment is required.

Children under 12 years of age should not take nimide tablets. No dose adjustment is required.

Patients with impaired renal function. For patients with mild or moderate renal impairment (creatinine clearance 30-80 ml/min), no dose adjustment is required, while severe renal impairment (creatinine clearance <30 ml/min) is a contraindication to the use of Nimid.

CHILDREN

Nimid tablets are contraindicated for children under 12 years of age.

Overdose

Symptoms of acute overdose of nonsteroidal anti-inflammatory drugs (NSAIDs) are usually limited to the following: apathy, drowsiness, nausea, vomiting, epigastric pain. These symptoms are usually reversible with maintenance therapy. Gastrointestinal bleeding, arterial hypertension, acute renal failure, respiratory depression, coma may occur, but such phenomena are rare. There have been reports of anaphylactoid reactions with the use of therapeutic doses of NSAIDs and with their overdose. There is no specific antidote. Treatment of overdose is symptomatic and supportive. There is no data on the elimination of nimesulide by hemodialysis, but if we take into account the high degree of binding of nimesulide to plasma proteins (up to 97.5%), it is unlikely that dialysis will be effective. If there are symptoms of overdose or after using a large dose of the drug within 4 hours after taking it, patients may be prescribed: artificial induction of vomiting and/or taking activated charcoal (60-100 g for adults) and/or taking an osmotic transport agent. Forced diuresis, increased urine alkalinity, hemodialysis and hemoperfusion may be ineffective due to the high degree of binding of nimesulide to plasma proteins. Kidney and liver functions should be monitored.

Adverse reactions

From the circulatory and lymphatic systems: anemia, eosinophilia, thrombocytopenia, pancytopenia, purpura.

From the immune system: hypersensitivity, anaphylaxis.

Metabolic disorder: hyperkalemia.

From the psyche: a feeling of fear, nervousness, nightmares.

From the nervous system: dizziness, headache, drowsiness, encephalopathy (Reye's syndrome).

From the organs of vision: blurred vision, visual disturbances.

From the organs of hearing and balance: vertigo (dizziness).

From the cardiovascular system: tachycardia, hemorrhage, lability of blood pressure, hot flashes, arterial hypertension, increased risk of arterial thrombotic complications, for example, myocardial infarction or stroke, heart failure.

From the respiratory system: shortness of breath, asthma, bronchospasm.

From the digestive tract: diarrhea, nausea, vomiting, including bloody vomiting, constipation, flatulence, gastritis, abdominal pain, dyspepsia, stomatitis, black bowel movements, bleeding in the digestive tract, ulcers and perforation of the duodenum/stomach, exacerbation of colitis and Crohn's disease.

From the hepatobiliary system: hepatitis; fulminant hepatitis, with a fatal outcome, including jaundice, cholestasis.

Skin: itching, skin rashes, increased sweating, erythema, dermatitis, urticaria, angioedema, facial edema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.

From the urinary system: dysuria, hematuria, urinary retention, renal failure, oliguria, interstitial nephritis.

General disorders: edema, malaise, asthenia, hyperthermia.

Laboratory indicators: increased levels of liver enzymes.

BEST BEFORE DATE.

3 years.

STORAGE CONDITIONS.

Store Nimid tablets at a temperature not exceeding 25°C in the original packaging. Keep out of the reach of children.

PACKAGE.

10 Nimid tablets in a blister, 1 blister in a cardboard package No. 10 (10*1). 10 tablets in a blister, 10 blisters in a cardboard package No. 100 (10*10).

Use during pregnancy and lactation

In the 1st and 2nd trimesters of pregnancy, the drug is drunk and rubbed in in exceptional cases: if the benefits to the health of the expectant mother outweigh the risks to the intrauterine development of the fetus. In the 3rd trimester and during breastfeeding, the use of Nimid is strictly contraindicated. The drug can cause increased swelling, provoke uterine bleeding and cause weakness in labor.

The medicine is not taken at the planning stage of pregnancy because it affects female fertility.

Overdose

Acute overdose of NSAIDs is usually manifested by lethargy, hypersomnia, nausea, vomiting, and epigastralgia, which are reversible with maintenance treatment. in rare cases, there is a possibility of bleeding in the digestive tract, hypertension, acute respiratory failure, respiratory depression, coma. anaphylactoid reactions may occur. There is no specific antidote. therapy is symptomatic and supportive. the effectiveness of hemodialysis is unlikely. in a 4-hour period after taking a high dose of the drug, vomiting should be artificially induced and/or an osmotic laxative and/or activated charcoal should be prescribed. Possible ineffectiveness of forced diuresis, increasing urine pH, hemodialysis and hemoperfusion. Monitoring of hepatic and renal functions is necessary.

How to use

Adults can take the tablets 2 times a day. The recommended dose is 100 mg. The maximum permissible daily dose should not exceed 400 mg.

Children over 12 years of age are prescribed treatment based on body weight: 1.5 mg/kg at a time. Children weighing more than 40 kg can take 100 mg tablets 2 times a day. The maximum permissible daily dose is 200 mg.

The tablets are taken after meals and must be washed down with plenty of water.

Adults and children take sachets 2 times a day after meals. The powder for oral suspension is prepared before administration.

The duration of treatment is determined by specialized specialists. Nimid for headaches is taken for no more than 1–2 days.

Areas with severe pain are treated with gel no more than 4 times a day. The ointment is applied in a thin layer without rubbing. After applying the gel, you should wash your hands well.

Composition and release form of Nimid

Nimid is available in various dosage forms:

• Nimid tablets containing 100 mg nimesulide. Auxiliary components are: microcrystalline cellulose, magnesium stearate, croscarmellose sodium, aerosil 200. Blisters contain 10 tablets;
• Nimid suspension containing 10 mg of nimesulide per 1 ml. In bottles of 60 ml;
• Nimid granular powder containing 100 mg of nimesulide. Auxiliary components: sodium saccharin, tabletose 80, citric acid monohydrate, povidone K-30, flavoring agent, aerosil 200. In sachets of 2 g. In a package of 30 sachets;
• Nimid gel containing 1 g of 10 mg of nimesulide. Auxiliary components of the gel are: propylene glycol, purified water, sodium hydroxide, flavor, methylparaben, carbomer 940, propylparaben, disodium edetate. In tubes of 20, 30 or 100 g.

Interaction with other drugs

The anesthetic should not be taken simultaneously with medications that have hepatotoxic properties. The combination of drugs can cause acute liver failure.

Combination with antiplatelet drugs can provoke the development of peptic ulcer.

While taking an anesthetic, the effect of diuretics and antihypertensive drugs may be weakened. If there is an urgent need for simultaneous therapy, renal function should be monitored.

Nimesulide increases the toxicity of Cyclosporine and Methotrexate.

special instructions

The lowest dose needed to control symptoms for the shortest period of time should be used.

If there is no effect (reduction in the intensity of pathological manifestations), therapy is completed.

Do not use in combination with hepatotoxic drugs and ethanol.

The use of NSAIDs during an infectious process of microbial etiology may mask the associated fever. Nimesulide therapy is completed if the patient develops fever or flu-like symptoms.

Therapy is completed when an ulcer or bleeding from the digestive tract appears.

If symptoms of liver damage occur, drug therapy is completed without resumption. In such patients, nimesulide should not be prescribed again.

Use with caution in patients with ulcerative colitis or Crohn's disease (possible exacerbation).

Do not use in combination with other painkillers and NSAIDs.

The likelihood of ulcers, bleeding or perforation of the digestive tract increases in parallel with an increase in the dose of NSAIDs in patients with a history of this pathology and in elderly patients. In this group of patients, therapy should begin with the minimum dose necessary to control symptoms.

These patients and patients who simultaneously receive acetylsalicylic acid for cardiac prophylaxis or other drugs that increase the likelihood of developing gastrointestinal complications require additional protection with proton pump inhibitors or misoprostol.

Caution is required in patients receiving GCS, selective serotonin reuptake inhibitors, acetylsalicylic acid or anticoagulants, as well as in patients (primarily elderly) with toxic damage to the digestive tract.

It is necessary to monitor the condition of patients with heart failure and/or hypertension, patients with excess fluid accumulation in the body or edema associated with the use of NSAIDs.

A number of NSAIDs (mainly with long-term use and in high doses) are associated with a small likelihood of developing arterial thrombosis. There is little information regarding nimesulide on this matter.

Before using nimesulide, a thorough analysis of the condition of patients with risk factors for cardiovascular pathology (smoking, hypertension, elevated blood lipid levels, diabetes mellitus), as well as in patients with coronary heart disease, acute heart failure, uncontrolled hypertension, pathology of peripheral arteries and/or cerebral vessels is required .

Due to the likelihood of decreased renal function in patients with renal impairment or heart failure, careful prescribing of the drug in this category of patients is necessary, with discontinuation of therapy if the condition worsens.

Due to the likelihood of bleeding and perforation of the digestive tract, disorders of renal, hepatic or cardiac functions, scrupulous monitoring of the condition of elderly patients is necessary.

Use with caution in patients with hemorrhagic diathesis.

It is not a substitute for acetylsalicylic acid to prevent cardiovascular pathology.

The likelihood of developing Lyell and Stevens-Johnson syndrome, as well as exfoliative dermatitis, is increased in patients with these reactions that occurred during the first month of the previous course of NSAID therapy.

If allergic reactions occur, including skin rashes and damage to the mucous membrane, immediate discontinuation of the drug is required.

The use of nimesulide is not recommended in patients who are planning pregnancy, as well as in the first and second trimester of pregnancy. In such cases, the minimum dose and duration of therapy are used.

The doctor should be notified if the patient develops pregnancy during the period of use of nimesulide.

Stop driving vehicles or using other mechanisms if a patient taking nimesulide develops cephalgia, dizziness or hypersomnia.

Popular questions about Nimid

How to take Nimid?

The medicine is taken only as directed, after a specialist has weighed the risks for the patient. Tablets and oral suspension are taken after meals. The maximum permissible daily dose for an adult is 400 mg.

How to dilute Nimid powder?

The contents of the sachet are poured into a container and 200–250 ml of warm water is added. The liquid is prepared immediately before use.

What does Nimid help with?

The drug has analgesic and anti-inflammatory effects. The medicine is used for the symptomatic treatment of pain in traumatology, surgery, gynecology, dentistry and ENT practice.

What is Nimid gel used for?

This form is used to treat diseases of the musculoskeletal system and inflammation of soft tissues caused by bruises, ligament damage, and sprains. The product relieves pain and promotes healing.

Can Nimid be taken for fever?

It is possible if the increase in body temperature is not associated with fever or influenza-like infections. In these cases, taking NSAIDs may complicate the diagnosis and course of the disease. An antipyretic drug is not indicated for low-grade fever.

Pharmacological properties

Pharmacodynamic parameters.
Nimesulide, the active ingredient of nimide, is a NSAID, a derivative of nitrobenzene. nimesulide inhibits the cog-mediated conversion of arachidonic acid into the precursor of prostaglandins, prostacyclin and thromboxane a2. Nimesulide has both analgesic, antipyretic and anti-inflammatory properties mediated by the action of TsOG-2, but has little effect on platelet function or loss of gastric cytoprotection associated with TsOG-1 activity. Pharmacokinetic parameters. Nimesulide has a rapid onset of action, with a high absorption rate when administered orally (Cmax in blood plasma is reached after 2–3 hours). All oral formulations demonstrate high and equivalent bioavailability. Nimesulide is tightly bound to plasma proteins (up to 97.5%) and has a moderately small volume of distribution. However, it is rapidly distributed in the synovial fluid.

Nimesulide is metabolized in oxidation reactions through the liver cytochrome P450 system (mainly CYP 2C9), mainly into a 4-hydroxy metabolite (4-OH-NME), which has pharmacological properties similar to the parent drug.

Elimination of nimesulide is progressive, T½ is 2–5 hours for the parent drug and 3–9 hours for its main metabolite 4-OH-NME.

It is excreted in the form of metabolites by the kidneys (about 50% of the administered dose) and in the feces (about 29%). In an unchanged state, 1–3% of the dose is excreted. There are no changes in pharmacokinetic parameters in elderly patients.

Note!

The description of the drug Nimid on this page is a simplified author’s version of the apteka911 website, created on the basis of the instructions for use.
Before purchasing or using the drug, you should consult your doctor and read the manufacturer's original instructions (attached to each package of the drug). Information about the drug is provided for informational purposes only and should not be used as a guide to self-medication. Only a doctor can decide to prescribe the drug, as well as determine the dose and methods of its use.